Name of compounds | Structure of the compounds | Molecular weights | Signaling pathways affected | References |
---|---|---|---|---|
R-Roscovitine |
| 354 | a) Abrogates induction of NF- κ B by preventing I κ B kinase (IKK) kinase activity, NF- κ B /p65-536ser phosphorylation b) Induces p53 by disrupting p53-MDM2 interaction | |
Flavopiridol |
| 438 | a) Blocks steps in the NF- κ B activation pathway such as I κ B α kinase and p65 nuclear translocation, and p65-529-ser phosphorylation b) Reversibly activates p53 by inhibiting MDM2 | |
Nutlin-3 |
| 581 | a) Inhibits NF- κ B targets ICAM1 and MCP1 transcription in p53 dependent manner. b) Potent inducer of p53 by inhibiting MDM2 interaction | |
Curcumin |
| 368 | a) Inhibits IKKkinase, promoinflammatory gene promoters such as TNF-2 α, COX-1, COX-2 b) p53 activation by inhibiting MDM2 c) modulation of other signaling pathways | |
Quinacrine |
| 473 | a) Inhibits both constitutive and inducible form of NF- κ B irrespective of the p53 status. b) Activates p53 | |
Curaxin (CBL 137) |
| 338 | a) Simultaneously suppress NF- κ B both basal and inducible states and activate p53 by targeting FACT b) Inhibits NF- κ B, activates p53 by inhibition of FACT complex | |
Benfur |
| 322 | Inhibits NF- κ B activity which is predominantly dependent on p53-mediated pathway | [258] |
Resveratrol |
| 228 | Inhibits NF- κ B /p65 and p53 transcriptional functions by deacetylation of specific residues | |
Pifithrin- α |
| 367 | Activation of NF- κ B through blockade of p53-p300 interaction | |
Bortezomib |
| 384 | Block of NF- κ B and stabilization of p53 by inhibiting E3 ubiquitin ligases | [265] |